M&A / Deals MSD concludes Terns acquisition to expand CML pipeline Pharmaceutical TechnologyMSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).HematologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML). Hematology Read full story Post navigation Previous: FDA Expands Market Access, Authorizes New ENDS ProductsNext: MSD concludes Terns acquisition to expand CML pipeline Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026